NCT04724538View on ClinicalTrials.gov

Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

March 15, 2021

Conditions
Covid19Pneumonia, Viral
Interventions
RADIATION

99mTc-pertechnetate aerosol

99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol

DRUG

99mTc-pertechnetate aerosol

99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol

Trial Locations (1)

125284

P. Hertsen Moscow Oncology Research Institute, Moscow

All Listed Sponsors
lead

National Medical Research Radiological Centre of the Ministry of Health of Russia

OTHER

NCT04724538 - Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19 | Biotech Hunter | Biotech Hunter